信立泰：创新小分子药物SAL0140片获得临床试验批准

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting indications such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - The drug aims to inhibit the synthesis of aldosterone, which is crucial for maintaining fluid and electrolyte balance, and is involved in various cardiovascular and renal diseases [1] Group 2: Mechanism of Action - Aldosterone is the most important mineralocorticoid hormone in the human body, activating mineralocorticoid receptors (MR) to regulate fluid and electrolyte balance [1] - Aldosterone synthase inhibitors are expected to mitigate end-organ damage caused by both genomic and non-genomic effects, potentially improving the progression of chronic kidney disease [1]